Michael Porter's Five Forces model is a framework to study the global immuno-oncology assay market. Strategic business managers trying to gain an edge over competing firms in the global immuno-oncology assay market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the global immuno-oncology assay market have been broken down and analyzed.
PORTER'S FIVE FORCES Analysis: Global Immuno-Oncology Assay Market
Threat of New Entrants
The threat of new entrants in the global immuno-oncology assay market is moderate to high, primarily due to the growing demand for precision oncology and advancements in biomarker technologies. While regulatory approvals, high R&D costs, and the need for technical expertise present barriers to entry, these are increasingly being overcome by startups and biotech firms entering the space with novel, targeted solutions. The fragmented nature of the market lowers entry barriers further, as new players can target niche segments or focus on specific technologies without directly competing with the larger incumbents. Additionally, ongoing innovation in immune profiling, multiplex assays, and liquid biopsy technologies continue to create openings for differentiated offerings, making it easier for new entrants to gain a foothold.
BARGAINING POWER OF SUPPLIERS
The bargaining power of suppliers in this market is low to moderate, influenced by the availability of multiple suppliers of key assay components such as reagents, antibodies, and consumables. Given the market fragmentation, suppliers are often competing to serve a broad base of diagnostic companies and laboratories, which limits their ability to dictate prices. However, in cases where companies are dependent on proprietary reagents or highly specialized biological materials, supplier power can increase slightly due to switching costs or limited availability. Nonetheless, most assay developers maintain relationships with multiple vendors, and global supply chain diversity helps keep supplier influence in check.
Threat of Substitutes
The threat of substitutes is moderate, with emerging diagnostic technologies such as liquid biopsies, next-generation sequencing (NGS), and advanced imaging techniques potentially replacing or complementing immuno-oncology assays. These alternatives may offer different types of clinical information or be more cost-effective in some scenarios. However, immuno-oncology assays provide unique value by offering biomarker-specific insights that guide immunotherapy decisions, making them difficult to fully replace. Moreover, their growing integration into clinical decision-making and pharmaceutical development pipelines strengthens their position, although continual technological evolution means the risk of substitution remains relevant in the long term.
Bargaining Power of Buyers
The bargaining power of buyers in the global immuno-oncology assay market is moderate to high, largely due to the fragmented supplier landscape and the presence of numerous options in terms of assay platforms, service providers, and diagnostic tools. Buyers, including hospitals, research institutions, pharmaceutical companies, and diagnostic labs, often have the leverage to negotiate pricing, demand customization, and expect performance validation, especially when purchasing in high volumes. The increasing cost pressures in healthcare systems and the push for value-based care also encourage buyers to seek cost-effective solutions, further increasing their influence over assay providers. This dynamic incentivizes assay developers to differentiate through innovation, partnerships, and value-added services.
Intensity of Rivalry
The intensity of competitive rivalry in the immuno-oncology assay market is high, fueled by the large number of players—ranging from global diagnostic companies to specialized biotech firms—vying for market share. Product differentiation is often based on assay sensitivity, turnaround time, biomarker range, regulatory approvals, and clinical utility. However, in such a fragmented market, many companies target overlapping applications, leading to price competition and frequent innovation cycles. As firms seek to establish long-term collaborations with pharmaceutical companies and healthcare institutions, the race to develop the most predictive and cost-effective assays intensifies. This environment of rapid technological advancement and pricing pressure sustains a high level of rivalry among both established and emerging market participants.
Impact of covid-19 on the Global Immuno-Oncology Assay Market
The COVID-19 pandemic exerted a moderately negative impact on the global immuno-oncology assay market. While the crisis led to short-term disruptions in clinical operations, diagnostics, and supply chains, the essential nature of oncology care and the long-term growth potential of immuno-oncology testing helped the market stabilize and recover more quickly than some other healthcare segments. The pandemic functioned as both a stress test and a transformation trigger for the sector, exposing vulnerabilities but also accelerating key trends in digital health and personalized medicine.
During the initial stages of the pandemic in 2020, healthcare systems globally shifted their focus almost entirely to managing the surge in COVID-19 cases. As a result, non-urgent procedures and routine cancer screenings were delayed or suspended, leading to a measurable decline in the volume of diagnostic testing, including immuno-oncology assays such as PD-L1, TMB (tumor mutational burden), and microsatellite instability (MSI) testing. Hospitals postponed elective procedures, and patients avoided clinical visits out of fear of contracting the virus, reducing the demand for both standalone and companion diagnostic assays.
Additionally, clinical trials in oncology faced disruptions, with many trials paused or slowed due to resource reallocation, recruitment challenges, and restricted patient mobility. Since immuno-oncology assays are integral to biomarker discovery and patient stratification in cancer trials, these disruptions led to a moderate decline in assay utilization and sales across the industry. However, unlike elective care, oncology treatment and research could not be paused indefinitely, so these declines were temporary, with many institutions resuming trials and diagnostics by mid to late 2021.
Global supply chains were severely affected by the pandemic, and the immuno-oncology assay market was not immune. Delays in the supply of critical raw materials, such as reagents, antibodies, and specialized assay kits, created bottlenecks for assay developers and diagnostic laboratories. Companies reliant on just-in-time inventory systems or international suppliers experienced significant procurement challenges, especially during lockdowns and transportation restrictions.
Furthermore, operational inefficiencies arose as laboratories and production facilities had to implement safety measures, limit staff presence, or temporarily shut down. Smaller assay developers, particularly those in early stages of commercialization, faced greater exposure to these disruptions, which limited their ability to meet ongoing or future diagnostic demands. While these issues did not result in a systemic collapse, they contributed to project delays and temporary revenue losses, constituting a moderate headwind for the market during the peak of the pandemic.
Another negative consequence of the pandemic was the short-term reallocation of research funding from oncology toward infectious disease efforts. Government grants, private investments, and institutional budgets were redirected to support the development of COVID-19 diagnostics, treatments, and vaccines.
